Medindia
Advertisement

Drug to Lower The Risk of Kidney Failure in Type 2 Diabetes

by Ramya Rachamanti on April 16, 2019 at 10:30 AM
Font : A-A+

Drug to Lower The Risk of Kidney Failure in Type 2 Diabetes

Canagliflozin decreases the risk of kidney failure by one-third in patients with type 2 diabetes and kidney disease, according to a new clinical trial.

"For the first time in 18 years, we have a therapy for patients with Type 2 diabetes and chronic kidney disease that decreases kidney failure," said Kenneth Mahaffey, MD, professor of medicine at the Stanford University School of Medicine and co-principal investigator of the trial. "Now, patients with diabetes have a promising option to guard against one of the most severe risks of their condition."

Advertisement


The trial involved 4,401 participants in 34 countries.

The drug, canagliflozin, improves on a nearly two-decades-old therapy that is currently the only treatment approved to protect kidney function in people with Type 2 diabetes. In the trial, canagliflozin also was found to reduce the risk of major cardiovascular events.
Advertisement

Canagliflozin increases the excretion of glucose through the kidneys. It has already been approved by the Food and Drug Administration to lower blood glucose in patients with Type 2 diabetes and to reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes and existing heart disease.

A paper describing the findings of the CREDENCE trial was published in The New England Journal of Medicine and presented at the International Society of Nephrology's World Congress of Nephrology in Melbourne. Mahaffey, who is director of the Stanford Center for Clinical Research, is the study's senior author.

The lead author is Vlado Perkovic, MBBS, PhD, executive director of The George Institute for Global Health Australia, and a professor of medicine at the University of New South Wales in Sydney.

'Definitive trial result'

"People with diabetes and kidney disease are at extremely high risk of kidney failure, heart attack, stroke and death," Perkovic said. "With this definitive trial result, we now have a very effective way to reduce this risk using a once-daily pill."

Participants in the trial received the best care available for kidney disease under current guidelines, a type of therapy called renin-angiotensin-aldosterone system, or RAAS, blockade. In addition, half were randomly selected to receive canagliflozin, while the other half were given a placebo.

The primary results of the study found that participants who took canagliflozin were 30 percent less likely than the placebo group to develop kidney failure or die from either renal failure or cardiovascular disease. Their risk of kidney failure or death from kidney failure was reduced by 34 percent, and the risk of hospitalization for heart failure or death due to cardiac causes decreased by 31 percent.

'Eagerly sought' treatment

People with diabetes can develop kidney disease because prolonged high blood sugar harms blood vessels in the kidney. In addition, diabetes often causes high blood pressure, which can stretch and weaken blood vessels in the organ.

For the past two decades, physicians have largely relied on RAAS blockade to prevent the deterioration of kidney function in diabetic patients. Although RAAS blockade lowers blood pressure and delays progression of kidney disease, patients undergoing this treatment remain at a high risk for renal failure and cardiovascular disease, as well as death from these conditions.

Given that the number of people with Type 2 diabetes worldwide is estimated to rise by 20 percent to 510 million in 2030, "a drug like canagliflozin that improves both cardiovascular and renal outcomes has been eagerly sought by both patients with Type 2 diabetes and clinicians caring for them,"

Mahaffey said.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Gonorrhea
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Acute Renal Failure Diabetic Retinopathy Drug Toxicity Glomerulonephritis Diabetes Diabetic Diet Otitis Media Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices 

Recommended Reading
Type 2 Diabetes
Globalization and changing lifestyles has made diabetes very common in developing countries so much ...
Acute Renal Failure
Acute renal failure is the sudden cessation of the functioning of kidneys, that can be due to reduce...
Diabetes
A comprehensive article on diabetes - both Type 1 and Type 2 diabetes, including : causes, signs, sy...
Diabetes - Essentials
Diabetes is a metabolic disease caused by insulin deficiency that leads to high blood sugar levels a...
Diabetes - Self-Monitoring of Blood Glucose (SMBG)
Self-Monitoring Of Blood Glucose (SMBG) is one of the greatest advancements in the management of Di...
Diabetic Diet
The diabetic diet most often recommended is high in dietary fiber (especially soluble fiber) and nut...
Diabetic Retinopathy
The term ‘diabetic retinopathy’ refers to changes in the retina which often occur in people with ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Glomerulonephritis
Glomerulonephritis is used to describe several kidney disease that damage the glomeruli. Glomerulone...
Insulin Delivery Devices
Insulin delivery devices have evolved drastically since their invention in 1922. They are all aimed ...
Otitis Media
Middle ear infection, or otitis media, is a common type of infection that may or may not accompany t...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use